R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates instead of dissipating. Every program produces reports, experiments, analyses, and decisions, and most of that knowledge is scattered across documents and people. When it cannot be found, it is repeated, and when a person leaves, it is lost.

The cost is concrete. Teams re-run experiments that were already done, revisit questions that were already answered, and lose the reasoning behind past decisions when the people who made them move on. This is the tribal knowledge problem, and it compounds negatively as an organization grows. This article explains how AI-powered knowledge management changes that, and how internal knowledge becomes most valuable when connected to the external research record.

What R&D knowledge management involves

R&D knowledge management spans two bodies of knowledge. The first is internal: research reports, experimental results, technical decisions, and the reasoning behind them. The second is external: the patents, scientific literature, and competitive activity that place internal work in context. The goal is to make both retrievable in a way that reflects how researchers actually think about a problem, rather than by filename or folder.

The defining requirement is retrieval by meaning. A researcher rarely knows the exact document title or keyword; they know the problem. Knowledge management is only useful if a question about a compound, a method, or a decision returns the relevant internal work regardless of how it was originally labeled.

Why traditional knowledge management fails in R&D

Traditional knowledge management relies on folders, tags, and keyword search over document stores. It fails in R&D for the same reasons keyword search fails elsewhere: the same concept is described in different words across teams and years, so a query built on expected terms misses relevant work. Documents are siloed by team and system, and the connection between a past experiment and a current question is invisible.

It also fails at the human boundary. When knowledge lives in individuals rather than a retrievable system, staff turnover erases it. A traditional document repository preserves files but not the ability to find the right one at the right moment, which is the part that actually matters.

How AI changes R&D knowledge management

AI-powered knowledge management applies semantic search to internal knowledge, so a question returns relevant reports, results, and decisions by meaning rather than exact keywords. An R&D ontology organizes that knowledge by technical concept and connects related work, so a current problem surfaces the past work that bears on it even when the vocabulary differs.

The larger shift is connecting internal knowledge to the external record. When internal research is organized in the same conceptual structure as the external patent and scientific literature, a single question can reach both: what the team already knows, and what the wider field has published or patented. That connection is what turns a static archive into an intelligence layer.

Why connected knowledge compounds

Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it. An experiment recorded today becomes findable the next time a related question arises; a past decision retains its reasoning; a current program is checked against both internal history and the external landscape before resources are committed. Instead of decaying as people leave and volume grows, the organization's knowledge becomes more valuable over time.

This is the difference between storing knowledge and compounding it. Storage preserves documents; compounding makes the whole body of work usable on every new question.

R&D knowledge management in practice

Cypris addresses this through its Knowledge Management product, which makes an organization's research knowledge retrievable and connects it to the external record. Internal work is organized through the same proprietary R&D ontology that structures a corpus of more than 500 million patents and scientific papers, so a single semantic query reaches both internal knowledge and the external patent and scientific literature.

Cypris Q, the platform's agentic layer, lets teams interrogate that combined knowledge in natural language and returns cited output, so a question about a compound or a program draws on internal history and external context at once. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is R&D knowledge management?

R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates rather than being lost to silos and turnover. It covers internal reports, experiments, and decisions, and connects them to the external patent and scientific record.

Why does R&D lose institutional knowledge?

R&D loses institutional knowledge because much of it lives in individuals and scattered documents rather than a retrievable system, so it disappears when people leave or when work cannot be found. This tribal knowledge problem leads teams to repeat experiments and lose the reasoning behind past decisions.

Why does traditional knowledge management fail in R&D?

Traditional knowledge management fails in R&D because folder-and-keyword systems miss work described in different terms across teams and years, and they silo documents by system. They preserve files but not the ability to find the right one at the right moment, which is the part that matters.

How does AI improve R&D knowledge management?

AI improves R&D knowledge management by applying semantic search, so a question returns relevant internal work by meaning rather than exact keywords. An R&D ontology organizes knowledge by technical concept and connects related work, and links internal knowledge to the external patent and scientific record.

What is tribal knowledge and why does it matter?

Tribal knowledge is the undocumented understanding held by individuals in an organization, such as why a decision was made or how a method actually works. It matters because it is lost when people leave, and capturing it in a retrievable system is a central goal of R&D knowledge management.

How does knowledge management connect internal work to external research?

Knowledge management connects internal work to external research by organizing both in the same conceptual structure, so a single question reaches internal reports and the external patent and scientific literature together. This places a team's own work in the context of what the wider field has published or patented.

What does it mean for knowledge to compound?

Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it, so its value grows over time. Instead of decaying as staff turn over and volume rises, the organization's body of work becomes more usable on every new question.

Is R&D knowledge management just a document repository?

R&D knowledge management is more than a document repository, because storage alone preserves files without making the right one findable at the right moment. The value is in retrieval by meaning and in connecting internal knowledge to the external record, not in archiving.

Which teams benefit most from R&D knowledge management?

Research-intensive organizations benefit most from R&D knowledge management, particularly in pharmaceuticals, chemicals, advanced materials, and energy, where programs are long, knowledge is technical, and turnover erases hard-won understanding. These teams gain the most from preserving and connecting institutional knowledge.

What is the best platform for R&D knowledge management?

The best platform for R&D knowledge management makes internal knowledge retrievable by meaning and connects it to the external research record. Cypris does this through its Knowledge Management product, organizing internal work through the same R&D ontology that structures a corpus of more than 500 million patents and scientific papers.

‍

mRNA therapeutics have moved from pandemic response to a broad modality, and their patent landscape is distinctive because the mRNA molecule is patented separately from the lipid nanoparticle that delivers it. This article addresses the construct itself. A therapeutic mRNA is engineered in several parts, and each is a distinct region of patenting: the modified nucleosides, such as pseudouridine variants, that reduce the innate immune response, an insight foundational to making mRNA usable in humans;¹ the five-prime cap that enables translation;² the untranslated regions that tune expression;³ the poly-A tail that stabilizes the molecule and, with the cap, defines the ends that are engineered for therapeutic performance;⁴ the sequence and codon optimization that improves output; and, increasingly, the self-amplifying and trans-amplifying designs that let a smaller dose replicate inside the cell. Rational-design analyses describe the construct as exactly this layered assembly, from cap through untranslated regions and open reading frame to poly-A tail, and the choice of nucleoside modification continues to shape immunogenicity.⁵,⁶ Because these elements can be claimed independently and are often held by different owners, and because delivery adds its own separate estate, freedom-to-operate for an mRNA product is a multi-layer, multi-owner analysis rather than a single clearance.

The field's IP has been defined by landmark disputes, which have raised the stakes across every layer. Foundational modified-nucleoside discoveries originated in academic work and are licensed through a chain of sublicenses, and the leading commercial developers have litigated over who owns and who may use the core construct technologies. Several of these cases have moved through courts in the United States and through the European Patent Office: one developer's settlement arrangements to resolve pending mRNA vaccine litigation with two others were entered on August 7, 2025,⁷ while a series of European construct patents were revoked or narrowed in opposition proceedings, with a further opposed patent maintained in amended form.⁸ The practical result is that a developer can hold a strong position on its own sequence and still face freedom-to-operate exposure on the nucleoside chemistry, the untranslated regions, or the tail, plus the separate delivery layer. This shows in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the mRNA vaccine and therapeutics set holds on the order of 16,694 families and grew from about 582 in 2020 to roughly 2,062 in 2024, with the most active assignees including ModernaTx, Translate Bio, CureVac, the University of Pennsylvania, MIT, and BioNTech, and the United States far ahead of China and Germany on geography; 2025 and 2026 counts are partial because of the publication lag.

The strategic picture turns on where defensible, hard-to-design-around IP sits. The foundational modified-nucleoside and core-structure estates are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in self-amplifying and trans-amplifying mRNA, in novel nucleoside modifications and sequence-engineering methods, in untranslated-region and structural designs that improve durability and expression, in enzymatic capping and manufacturing methods, and in mRNA applications beyond vaccines.⁷ Self-amplifying mRNA has now reached the market: the first self-amplifying mRNA vaccine, which encodes a replicase alongside the antigen so the molecule copies itself inside the cell, was approved in Japan in 2023 and by the European Commission in February 2025, though not, as of this writing, in the United States.⁹ Circular RNA and other next-generation constructs are a further frontier. Reading the landscape by construct layer and by owner, and tracking both the patents and the underlying RNA-biology research, is what separates a workable position from a blocked one.

What creates FTO risk in mRNA constructs

Modified-nucleoside claims. These cover the chemistries, such as pseudouridine variants, that reduce immune activation, a foundational and heavily licensed layer.¹,⁶

Cap and untranslated-region claims. These cover the five-prime cap and the untranslated regions that enable and tune translation, a distinct expression-control layer.²,³

Poly-A tail and stability claims. These cover the tail and other end-engineering technologies, a separately owned and actively litigated layer.⁴

Sequence and codon-optimization claims. These cover methods to improve protein output from a given sequence, which can carry their own IP.

Self-amplifying and next-generation-construct claims. These cover self-amplifying, trans-amplifying, and circular-RNA designs, an emerging and comparatively open layer.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant nucleoside, cap, untranslated-region, tail, and self-amplifying claims regardless of terminology, attribution that resolves academic and commercial owners and the sublicense chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because RNA-biology advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as mRNA therapeutics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by construct layer, modified nucleoside, cap, untranslated region, poly-A tail, and self-amplifying design, and normalizes academic and commercial owners and their sublicense chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list, and can separate the construct estate from the delivery estate. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new modifications and constructs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is mRNA construct IP separate from delivery IP? mRNA construct IP is separate from delivery IP because the mRNA molecule and the lipid nanoparticle that carries it are distinct inventions with distinct owners. The construct covers the nucleosides, cap, untranslated regions, tail, and sequence; the delivery covers the lipid formulation. Freedom-to-operate must clear both estates separately.

Why were modified nucleosides so important? Modified nucleosides were important because replacing a natural nucleoside with a modified form, such as a pseudouridine variant, sharply reduced the innate immune response that had previously made mRNA unsuitable as a drug. This breakthrough helped enable therapeutic mRNA. The foundational nucleoside estates are therefore central to the landscape.

What claim types create FTO risk in mRNA constructs? Five claim types create FTO risk: modified-nucleoside claims, cap and untranslated-region claims, poly-A tail and stability claims, sequence and codon-optimization claims, and self-amplifying and next-generation-construct claims. Each covers a distinct layer and can be held by a different owner. The nucleoside and stability layers have been especially contested.

Why has mRNA IP been so heavily litigated? mRNA IP has been heavily litigated because the modality became commercially enormous very quickly, foundational construct technologies are held by a small number of parties, and their scope overlaps. Disputes have run through courts and the European Patent Office, with some resolved by settlement, including arrangements entered in August 2025, and others contested in opposition proceedings. The outcomes shape licensing across the field.

Has a self-amplifying mRNA product been approved? Yes. The first self-amplifying mRNA vaccine, which encodes a replicase so the mRNA copies itself inside cells, was approved in Japan in 2023 and by the European Commission in February 2025. It had not been approved in the United States as of this writing. Self-amplifying designs aim to achieve a given effect at a lower dose.

Where is the white space in mRNA therapeutics? The white space includes self-amplifying and trans-amplifying mRNA, novel nucleoside modifications and sequence engineering, untranslated-region and structural designs, enzymatic capping and manufacturing, circular RNA, and applications beyond vaccines. The foundational construct layers are crowded and licensed. The durable, defensible value is in next-generation constructs and new applications.

What software helps analyze the mRNA therapeutics patent landscape? Software for the mRNA landscape should resolve academic and commercial owners and sublicense chains to canonical entities, separate the construct and delivery estates, cluster the nucleoside, cap, untranslated-region, tail, and self-amplifying layers, search patents and scientific literature semantically, and monitor disputes and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need mRNA patent landscape and FTO analysis? mRNA patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at mRNA and vaccine companies, as well as investors assessing mRNA assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2). https://doi.org/10.1016/j.immuni.2005.06.008
2. Kore, A. R., Senthilvelan, A., & Shanmugasundaram, M. (2022). Recent advances in modified cap analogs for mRNA-based vaccines. The Chemical Record, 22(9). https://doi.org/10.1002/tcr.202200005
3. Zhang, H., et al. (2024). Optimization of the 5′ untranslated region of mRNA vaccines. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-70792-x
4. Jemielity, J., et al. (2023). Chemical modifications of mRNA ends for therapeutic applications. Accounts of Chemical Research, 56(20). https://doi.org/10.1021/acs.accounts.3c00442
5. To, K. K. W., & Cho, W. C. S. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 16(11). https://doi.org/10.1080/17460441.2021.1935859
6. Liu, Y. (2026). The impact of nucleotide modifications on the immune responses of mRNA vaccines. https://doi.org/10.54097/bmddk068
7. CureVac N.V. (2025). CureVac announces resolution of patent litigation with Pfizer/BioNTech (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
8. CureVac N.V. (2025). CureVac receives positive validity decision from the European Patent Office in litigation against BioNTech SE (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925028798/tm2510706d1_ex99-1.htm
9. European Medicines Agency (2024). Kostaive (zapomeran): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/kostaive-epar-public-assessment-report_en.pdf

‍

Antibody-drug conjugates are among the most active areas of oncology drug development, and their patent landscape is distinctive because an ADC is a modular product whose components are patented separately. An ADC joins a monoclonal antibody to a cytotoxic payload through a chemical linker, using a defined conjugation chemistry and a specified drug-to-antibody ratio. Each of these elements, the antibody, the linker, the payload, the conjugation site and chemistry, and the ratio, can be claimed independently, so freedom-to-operate risk is layered across several distinct patent families held by different owners. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims, and peer-reviewed analysis of ADC intellectual property has long stressed that the assessment must cover every layer, not the molecule as a whole.¹

The landscape has grown intensely. A peer-reviewed update to the ADC patent literature notes that, a decade after the first ADC patent-landscape review, the basic principles still apply but the field has expanded and matured substantially, with next-generation payloads, linkers, and site-specific conjugation driving new filings.² That expansion is visible in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, ADC-specific patent families more than doubled from about 2,645 in 2018 to about 5,949 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag. The growth has been propelled by potent topoisomerase-1 payloads such as the deruxtecan and govitecan classes, new linker and site-specific conjugation technologies, and the expansion of ADCs from hematologic cancers into solid tumors. Peer-reviewed patent reviews map the issued patents onto specific linker and payload technologies,³ and document filing activity concentrated among a small set of leading developers, with more than a dozen approved ADCs and a large clinical pipeline behind the trend.⁴ Within the Cypris corpus, conjugation and site-specific chemistry and the linker layer are the most heavily worked parts of the ADC set, consistent with where litigation and FTO risk concentrate.

Litigation has made the stakes concrete, and it has centered on the linker layer. In the multi-year dispute between Seagen and Daiichi Sankyo over the linker technology used in a blockbuster HER2-targeted ADC, a jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and non-enablement and vacating the damages award.⁵ The court reasoned that the priority disclosure did not convey possession of the specific claimed subgenus of linkers and that a broad functional claim was not enabled.⁵ For developers, the practical lesson is twofold: the linker and conjugation layer is heavily contested and a frequent source of FTO risk, and the proprietary payload estates built around leading platforms, such as the DXd payload, create freedom-to-operate exposure for follow-on and biosimilar ADCs in markets where those estates are in force. That exposure is concentrated: across the Cypris corpus, the most active assignees in the ADC-specific set include Genentech, Seagen, Daiichi Sankyo, Regeneron, Immunomedics, and ImmunoGen, several of which anchor the payload and linker estates most likely to surface in an FTO search. Because applications publish about eighteen months after filing, the newest linker, payload, and conjugation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What creates FTO risk in ADCs

Antibody claims. These cover the targeting antibody and its engineering, a distinct layer that can implicate separate antibody IP.

Linker claims. These cover cleavable and non-cleavable linkers and their chemistry, the layer most heavily litigated, as the Seagen v. Daiichi Sankyo dispute demonstrates.⁵

Payload claims. These cover the cytotoxic agent, including proprietary payload estates built around specific classes, which create FTO exposure for follow-on products.

Conjugation and site-specific claims. These cover how payload and antibody are joined and where, an area of intense recent innovation and patenting.³

Drug-to-antibody ratio and formulation claims. These cover the ratio and the finished formulation, adding further independently claimable layers.

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, actively litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant antibody, linker, payload, and conjugation claims regardless of terminology, attribution that resolves the many owners to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and litigation developments. Because ADC advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the landscape is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as antibody-drug conjugates across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, antibody, linker, payload, and conjugation, and normalizes owners to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation linkers and payloads emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for antibody-drug conjugates? Freedom-to-operate is hard for antibody-drug conjugates because an ADC is a modular product whose antibody, linker, payload, conjugation chemistry, and drug-to-antibody ratio are each independently patentable and often held by different owners. Clearing one layer does not clear the others. FTO must therefore be assessed layer by layer across multiple patent families.

What are the main claim types in the ADC landscape? The main claim types are antibody claims, linker claims, payload claims, conjugation and site-specific claims, and drug-to-antibody-ratio and formulation claims. Each covers a distinct layer of the ADC and can independently create infringement risk. The linker and conjugation layers are especially heavily patented and litigated.

What was the Seagen v. Daiichi Sankyo dispute about? The Seagen v. Daiichi Sankyo dispute concerned linker technology used in a blockbuster HER2-targeted ADC. A jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and enablement and vacating the award. It illustrates how the linker layer drives ADC freedom-to-operate risk and how even a trial win can be undone on validity grounds.

How fast is ADC patenting growing? ADC patenting has grown rapidly, with ADC-specific patent families more than doubling between 2018 and 2024 in the Cypris corpus. Growth has been driven by potent topoisomerase-1 payloads, new linker and site-specific conjugation technologies, and expansion from hematologic cancers into solid tumors. Because applications publish about eighteen months after filing, recent activity is under-represented.

What is a payload estate and why does it matter for FTO? A payload estate is the set of patents an organization holds around a specific cytotoxic payload class and its use in ADCs. It matters for FTO because a strong payload estate, such as the one around the DXd payload, can create infringement exposure for follow-on and biosimilar ADCs in markets where it is in force. Developers must assess payload IP as a distinct layer.

Why does ADC analysis need scientific literature? ADC analysis needs scientific literature because linker, payload, and conjugation advances appear in research before they are patented, so the literature gives the earliest signal of where the landscape is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need ADC patent landscape and FTO analysis? ADC patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at pharmaceutical and biotech companies developing ADCs, payloads, linkers, and conjugation platforms, as well as investors assessing ADC assets. The modular, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an ADC landscape need to be? An ADC landscape needs to be continuously current, because litigation is active, next-generation linker and payload filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

‍

Battery circularity, the recycling, reuse, and repurposing of batteries, has become the fastest-growing area of battery patenting, and its landscape is a map of the coming competition over critical minerals. According to a joint study by the European Patent Office and the International Energy Agency, international patent families related to battery circularity grew at an average of 42 percent per year from 2017 to 2023, compared with 16 percent for rechargeable battery manufacturing overall and 2 percent across all technical fields.¹ Over the decade the number of these families rose roughly sevenfold.¹ The driver is structural: more than one in four cars sold globally in 2025 was electric, and around 1.2 million electric-vehicle batteries could reach end of life in 2030, rising to 14 million by 2040, so managing and reclaiming that volume is both an environmental necessity and a supply-chain strategy.¹

The landscape is geographically concentrated and shifting quickly. Asian applicants accounted for 63 percent of battery-circularity patent families in 2023, and China's share rose from 5 percent in 2013 to 29 percent in 2023, with Brunp, the recycling subsidiary of a major battery maker, overtaking established Japanese and Korean firms to become the most active filer.¹ European companies and research institutes account for roughly 20 percent of families, with particular strength in the collection and pre-processing of used batteries and in chemical transformation to recover raw materials, reflecting Europe's current role more as a battery user than a producer.¹ An independent count across the Cypris corpus of more than 500 million patents and scientific papers reproduces the same picture: China holds roughly two-thirds of the recycling-specific family set, well ahead of the United States, Germany, South Korea, and Japan, and Brunp is the single most active assignee, ahead of chemical and battery-materials firms such as BASF and Sumitomo Metal Mining. The strategic significance is large: energy storage now represents about 40 percent of all energy-related patenting and is heading toward half, and recycled materials could meet more than a fifth of demand for lithium, nickel, and cobalt by 2040.¹

The technology landscape divides into distinct stages, each a region of patenting. A peer-reviewed patent-network analysis of lithium-ion battery recycling covering 1990 to 2024 finds activity rising steeply since around 2020, with China leading and international collaboration remaining limited,² and bibliometric analysis of the field documents the same long-run acceleration in recycling research and patenting.³ Across the Cypris corpus, hydrometallurgy is the most patented chemical-recovery route, well ahead of pyrometallurgy, while direct recycling and cathode regeneration remain comparatively nascent; a large, separate cluster covers collection, pre-processing, and separation, the earlier stage where Europe is comparatively strong. Metal recovery and cathode regeneration are where much of the chemical innovation and value concentrate, with key work focused on improving leaching efficiency, developing purification methods, and relithiation strategies that restore spent cathode materials. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is even more active than the figures show.

Where the battery-circularity white space is

Direct cathode regeneration. Restoring spent cathode material directly, rather than breaking it down to metals, is a higher-value route that remains comparatively nascent in the patent record, leaving room for defensible positions.²

Efficient metal recovery. Improving leaching efficiency and purification for lithium, nickel, and cobalt is where much chemical innovation concentrates and where recovery economics are decided.²

Collection and pre-processing. Sorting, dismantling, and safe handling, including remote-handling technologies, are an earlier stage where activity is comparatively less crowded and where European applicants are relatively strong.¹

Reuse and repurposing. Second-life applications for batteries, distinct from material recovery, are a separate and growing layer.

Design for recyclability. Battery designs that ease disassembly and recovery link circularity back to manufacturing and are an emerging cross-over area.

How AI-powered landscape and white space analysis helps

Resolving a fast-growing landscape across stages, chemistries, and geographies requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by recovery route and processing stage across varied terminology, attribution that normalizes filers to canonical entities and tracks shifting leadership, and continuous monitoring that keeps pace with a field growing far faster than average. Because circularity advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier is moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-growing energy fields such as battery circularity across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by recovery route, hydrometallurgy, direct regeneration, separation, and pyrometallurgy, and by processing stage, and normalizes filers to canonical entities, so a team can resolve which routes and stages are crowded and which remain open as white space, and can track shifting leadership as new entrants rise. Semantic search across patents and scientific literature connects filings to the underlying materials and process research, which is where circularity advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is battery-recycling patenting growing? Battery-recycling patenting is growing very fast. According to the EPO and IEA, international patent families in battery circularity grew at an average of 42 percent per year from 2017 to 2023, versus 16 percent for battery manufacturing and 2 percent across all technical fields, roughly a sevenfold increase over the decade. It is now growing faster than battery patenting in general.

Who leads in battery-circularity patents? Asian applicants held 63 percent of battery-circularity patent families in 2023. China's share rose from 5 percent in 2013 to 29 percent in 2023, and Brunp, a major battery maker's recycling subsidiary, overtook established Japanese and Korean firms as the most active filer. European companies and research institutes hold roughly 20 percent, with strength in collection and pre-processing. An independent Cypris-corpus count reproduces China's roughly two-thirds share and Brunp's lead.

What technologies does the battery-recycling landscape cover? The battery-recycling landscape covers collection, sorting, and dismantling; mechanical processing; and metal recovery and cathode regeneration. Analysis of the patent record finds hydrometallurgy the most patented chemical-recovery route, ahead of pyrometallurgy, with direct recycling still comparatively nascent. Innovation concentrates on leaching efficiency, purification, and relithiation.

Why is battery circularity strategically important? Battery circularity is strategically important because it is a secondary supply of critical minerals. Around 1.2 million electric-vehicle batteries could reach end of life in 2030 and 14 million by 2040, and recycled materials could meet more than a fifth of lithium, nickel, and cobalt demand by 2040. This links recycling to supply-chain security and energy security.

Where is the white space in battery recycling? The white space in battery recycling includes direct cathode regeneration, efficient metal recovery and purification, collection and pre-processing including remote handling, reuse and repurposing for second-life applications, and design for recyclability. Metal recovery and cathode regeneration are where chemical innovation concentrates. The higher-value opportunities are in routes that improve recovery economics.

Why does battery-recycling analysis need scientific literature? Battery-recycling analysis needs scientific literature because process and materials advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use battery-recycling patent landscape analysis? Battery-recycling patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery makers, recyclers, automotive and energy companies, materials developers, and their partners, as well as investors and policymakers. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

How do you keep a battery-recycling landscape current? Keeping a battery-recycling landscape current requires continuous monitoring, because the field is growing far faster than average, leadership is shifting quickly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.

Endnotes

1. International Energy Agency & European Patent Office (2026). Battery circularity: innovation trends for a future source of critical materials. IEA, Paris. https://www.iea.org/reports/battery-circularity
2. von Delft, S., Schlehuber, S., & Hemmelder, A. (2025). Uncovering collaboration and knowledge areas in lithium-ion battery recycling. EES Batteries. https://doi.org/10.1039/d5eb00056d
3. Li, Y., Guo, Y., Guan, J., Zhang, X., & Lou, X. (2022). Global trend for waste lithium-ion battery recycling from 1984 to 2021: a bibliometric analysis. Minerals, 12(12), 1514. https://doi.org/10.3390/min12121514

‍

AAV gene therapy has crossed into commercial reality, and its patent landscape is distinctive because an AAV therapy is a modular product whose parts are patented separately. An adeno-associated virus vector delivers a therapeutic gene by packaging it inside an engineered protein shell, the capsid, whose surface engages target-cell receptors and whose fate through endocytosis, endosomal escape, and nuclear import determines where the therapy goes and how the immune system responds to it.¹ The intellectual property divides across distinct regions, each a distinct area of patenting: the capsid, spanning natural serotypes and, increasingly, engineered capsids produced by directed evolution, structure-guided design, and machine-learning-guided design;²,³,⁴,⁵ the strategies that address immunogenicity, because pre-existing neutralizing antibodies exclude many patients and the immune response generally prevents redosing;⁶,⁷ the transgene expression cassette, including the promoter and regulatory elements that control where and how strongly the gene is expressed; and the manufacturing process, where empty-capsid content, host-cell productivity, and the ratio of full to empty particles remain challenges at commercial scale.⁸ Because a therapy depends on several of these layers and they are often held by different owners, freedom-to-operate for an AAV product is a multi-layer, multi-owner analysis rather than a single clearance.

The competitive and legal environment has raised the stakes across every layer. Capsid engineering is the most active area of IP, with specialized platform companies developing next-generation capsids that target specific tissues such as the brain, muscle, and retina and that aim to evade pre-existing immunity, and licensing these platforms to larger developers.⁴,⁹ At the same time, foundational vector patents have been litigated, with the Federal Circuit deciding an appeal on core AAV vector claims in early 2026, so the boundaries of the foundational estate continue to be tested even as the field advances.¹⁰ The commercial ground is set by a broader wave of approved products: as of the 2024 review window, the US Food and Drug Administration had approved fourteen cellular and gene therapy products across the modality, of which the AAV-based Luxturna (voretigene neparvovec-rzyl) for RPE65-mediated inherited retinal dystrophy remains the AAV exemplar, first approved in the United States in 2017 and separately authorized in the European Union.⁴,¹¹,¹² Because applications publish about eighteen months after filing, the newest capsid and immune-evasion filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic question is where defensible, hard-to-design-around IP sits. Across the Cypris corpus of more than 500 million patents and scientific papers, the AAV capsid-variant set holds on the order of 12,966 families and grew from about 828 in 2020 to roughly 1,818 in 2024, with the most active assignees led by the University of Pennsylvania, Voyager Therapeutics, the University of Massachusetts, Genzyme, and UC San Diego, and the United States far ahead of China, France, and the United Kingdom on geography; 2025 and 2026 counts are partial because of the publication lag. The most active and high-value ground is in engineered capsids that both target a tissue precisely and evade pre-existing immunity, because these directly address the field's central limitations, and receptor-guided and machine-learning-guided capsid design are advancing quickly here.²,³,⁴,⁵ Redosing and immune-modulation technologies are a distinct and comparatively open layer,⁶,⁷ as are manufacturing methods that raise the full-to-empty ratio and lower cost,⁸ and expression-cassette designs that improve durability and tissue specificity.⁴,⁹ Reading the landscape by layer and by owner, and tracking both the patents and the underlying virology and immunology research, is what separates a workable position from a blocked one.

What creates FTO risk in AAV gene therapy

Capsid claims. These cover natural serotypes and engineered capsids from directed evolution, structure-guided, and machine-learning design, the most active and contested layer.²,³,⁴,⁵

Immunogenicity and redosing claims. These cover strategies to evade pre-existing antibodies and enable redosing, a distinct and high-value layer given the field's central limitation.⁶,⁷

Transgene and expression-cassette claims. These cover promoters, regulatory elements, and the engineered transgene that control expression, a separately owned layer.

Manufacturing and purification claims. These cover producer systems, full-to-empty separation, host-cell productivity, and purification, where practical, hard-to-design-around barriers concentrate.⁸

Tissue-targeting claims. These cover receptor-guided and tissue-specific delivery, which can independently constrain a competing program.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant capsid, immunogenicity, cassette, and manufacturing claims regardless of terminology, attribution that resolves the many owners and license chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because AAV advances appear in virology and immunology literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as AAV gene therapy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, capsid, immunogenicity, expression cassette, and manufacturing, and normalizes developer, platform-specialist, and academic owners and their license chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new capsids and immune-evasion strategies emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for AAV gene therapy? Freedom-to-operate is hard for AAV gene therapy because a therapy is built from a capsid, an immune-evasion strategy, a transgene expression cassette, and a manufacturing process, each independently patentable and often held by different owners. The capsid layer alone is heavily engineered and contested. FTO must be assessed layer by layer across multiple estates.

Why is the capsid the key layer? The capsid is the key layer because it determines which tissues the therapy reaches and how the immune system responds, and it is where most engineering and patenting activity concentrates. Engineered capsids from directed evolution, structure-guided design, and machine learning aim to target tissues and evade immunity. That makes capsid IP the most active battleground.

What claim types create FTO risk in AAV therapy? Five claim types create FTO risk: capsid claims, immunogenicity and redosing claims, transgene and expression-cassette claims, manufacturing and purification claims, and tissue-targeting claims. Each covers a distinct layer and can be held by a different owner. The capsid and manufacturing layers are especially decisive.

Why do immunity and redosing matter so much? Immunity and redosing matter because pre-existing neutralizing antibodies exclude many patients from AAV therapy, and the immune response to a first dose generally prevents giving a second, so AAV is typically a single-dose modality. Technologies that evade pre-existing immunity or enable redosing address a central limitation. They are therefore a distinct, high-value layer.

Where is the white space in AAV gene therapy? The white space includes engineered capsids that target tissues and evade pre-existing immunity, redosing and immune-modulation technologies, manufacturing methods that raise the full-to-empty ratio, and expression-cassette designs that improve durability and specificity. Natural serotypes and liver-directed approaches are comparatively crowded. The durable, defensible value is in capsids, immune evasion, and manufacturing.

Why does AAV analysis need scientific literature? AAV analysis needs scientific literature because new capsids, immune-evasion strategies, and manufacturing advances appear in virology and immunology research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the AAV gene therapy patent landscape? Software for the AAV landscape should resolve developer, platform-specialist, and academic owners and license chains to canonical entities, cluster the capsid, immunogenicity, cassette, and manufacturing layers, search patents and scientific literature semantically, and monitor litigation and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need AAV patent landscape and FTO analysis? AAV patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at gene therapy and pharmaceutical companies, capsid-platform specialists, academic technology-transfer offices, and investors assessing gene therapy assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Hao, Y., & Xiang, J. (2023). Biophysical characterization of the AAV capsid through the viral transduction life cycle. Journal of Genetic Engineering and Biotechnology, 21. https://doi.org/10.1186/s43141-023-00518-5
2. Fakhiri, J., Becker, S., & Grimm, D. (2022). Fantastic AAV gene therapy vectors and how to find them: random diversification, rational design and machine learning. Pathogens, 11(7), 756. https://doi.org/10.3390/pathogens11070756
3. Qi, Y., et al. (2025). Artificial intelligence-based approaches for AAV vector engineering. Advanced Science, 12. https://doi.org/10.1002/advs.202411062
4. Gao, F., et al. (2024). AAV engineering and load strategy for tropism modification, immune evasion and enhanced transgene expression. International Journal of Nanomedicine, 19. https://doi.org/10.2147/ijn.s459905
5. Fu, W., et al. (2024). Machine-learning-guided directed evolution for AAV capsid engineering. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128286593240226060318
6. Barnes, C., Scheideler, O., & Schaffer, D. (2019). Engineering the AAV capsid to evade immune responses. Current Opinion in Biotechnology, 60. https://doi.org/10.1016/j.copbio.2019.01.002
7. Meumann, N., Rodríguez-Márquez, E., & Büning, H. (2020). AAV capsid engineering in liver-directed gene therapy. Expert Opinion on Biological Therapy, 21(6). https://doi.org/10.1080/14712598.2021.1865303
8. Yoon, S., Lee, D., et al. (2024). Decoding cellular mechanism of rAAV and engineering host-cell factories. Biotechnology Advances, 72. https://doi.org/10.1016/j.biotechadv.2024.108322
9. Marković, I., et al. (2025). AAV gene therapy drug development and translation of engineered ocular and neurotropic capsids. Clinical and Translational Science, 18. https://doi.org/10.1111/cts.70428
10. RegenxBio Inc. v. Sarepta Therapeutics, Inc., No. 24-1408 (Fed. Cir. Feb. 20, 2026).
11. U.S. Food and Drug Administration. Approved cellular and gene therapy products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
12. U.S. Food and Drug Administration (2017). Luxturna (voretigene neparvovec-rzyl). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna

‍

Chemical intelligence unifies three data types that chemistry R&D depends on: patents, scientific literature, and chemical structure data. A question about a compound, a reaction, or a material rarely lives in one of these alone. The relevant disclosure may sit in a patent claim, a journal paper, or a structure database, and the connection between them is where the insight is.

Most tools address only one layer. Structure databases index compounds, patent databases index filings, and literature databases index papers, and researchers toggle between them manually. That fragmentation is slow and lossy: a compound found in one system is not automatically linked to the patents that claim it or the papers that characterize it.

In 2026, AI-powered chemical intelligence closes that gap. Semantic search and a structured model of the field retrieve across patents, papers, and structures together. This article defines chemical intelligence, explains why siloed search falls short, and describes how the AI-powered approach works.

What chemical intelligence covers

Chemical intelligence spans the full evidence base for a compound or material. It includes patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is unification: the same compound is connected across every source in which it appears.

This is broader than chemical patent search. Patent search answers what has been filed; chemical intelligence answers what is known about a compound or material across the literature, the patent record, and structure data at once, which is what R&D and IP teams in chemistry, materials, and pharmaceuticals actually need.

Why siloed chemical search falls short

Siloed search forces a researcher to run the same question three times, in three systems, with three query languages, and then reconcile the results by hand. Connections are missed because no single tool sees all the evidence. A compound identified in a structure database is not tied to the patents that claim it or the papers that report its properties.

Keyword search compounds the problem. In chemistry, the same compound or reaction is described under different names, notations, and terminology, so a keyword query misses filings and papers that use unexpected language. The volume of new chemistry filings and publications continues to rise, widening the gap between what a manual, siloed search finds and what actually exists.

How AI-powered chemical intelligence works

AI-powered chemical intelligence applies semantic search across a unified corpus of patents and scientific literature, retrieving disclosures by meaning rather than exact terms. This surfaces the papers and filings that describe a compound or reaction in different language, which keyword search overlooks.

An R&D ontology links the layers. Because an ontology is a structured map of technical concepts and their relationships, it connects a compound to the patents that claim it, the papers that characterize it, and the technology domains it belongs to. That linkage is what turns three separate result sets into one coherent picture.

Agentic workflows then operate on that picture. On an AI-native platform such as Cypris, an agent can assess chemical freedom-to-operate at the claim level, assemble a competitive landscape of a chemical technology, or monitor a compound class continuously, retrieving across patents, papers, and structure data and returning cited output.

Where chemical intelligence is used

Chemical freedom-to-operate is a primary use. Chemical FTO assesses whether making, using, or selling a compound or formulation would infringe active patent claims, and it depends on retrieving claims that may describe the same chemistry in different terms. Competitive monitoring is another: teams track competitor chemical patents and pipelines continuously rather than rebuilding a picture each quarter.

Materials and formulation scouting is a third. Researchers use chemical intelligence to identify sustainable material alternatives, track new synthesis trends, and find who is active in a compound class, drawing on patents and literature together. Each of these questions is answered more completely when structure, patent, and literature evidence is unified.

Chemical intelligence in practice

Cypris is an AI-native R&D intelligence platform that unifies chemical evidence across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology, alongside chemical compound data. The ontology links compounds to the patents that claim them and the papers that characterize them, so semantic search retrieves across all of it rather than one silo.

Cypris Q, the platform's agentic layer, runs chemical FTO, landscape, and prior art workflows and returns cited output, while Agentic Monitoring tracks compound classes and competitor chemical activity continuously across patents, scientific literature, chemical compound data, and regulatory sources. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

Each compound page in our directory shows a slice of these connections: who is patenting, which classifications cluster, which research groups are active. You can browse it freely here.

FAQ

What is a chemical intelligence platform?

A chemical intelligence platform unifies patents, scientific literature, and chemical structure data so R&D teams can search all three together rather than in separate silos. It connects a compound to the patents that claim it and the papers that characterize it, which is broader than chemical patent search alone.

What data does chemical intelligence cover?

Chemical intelligence covers patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is that the same compound is linked across every source in which it appears.

Can I search patents and chemical structures together?

Searching patents and chemical structures together requires a platform that unifies both in one corpus and links compounds to the filings that claim them. An AI-powered chemical intelligence platform does this with semantic search and an R&D ontology, so a compound and its patent coverage are connected rather than searched separately.

Is there a platform to search scientific papers and chemical structures?

A chemical intelligence platform searches scientific papers and chemical structures together by unifying literature and compound data in a single corpus. This matters because a compound's properties are often reported in papers before or alongside its appearance in patents, so searching both together gives a fuller picture.

How does AI improve chemical patent research?

AI improves chemical patent research by applying semantic search, which retrieves filings that describe the same compound or reaction in different names and notations. Combined with an R&D ontology that links compounds to their patents and papers, it surfaces evidence that keyword search across a single database misses.

What is chemical freedom-to-operate (FTO)?

Chemical freedom-to-operate assesses whether making, using, or selling a compound or formulation would infringe active patent claims. It depends on retrieving claims that may describe the same chemistry in different terms, which is why semantic search across a unified corpus is central to reliable chemical FTO.

How do R&D teams monitor competitor chemical patents?

R&D teams monitor competitor chemical patents most effectively with continuous, AI-powered monitoring that interprets new filings in the context of a compound class or technology domain. This replaces quarterly manual rebuilds and surfaces competitor chemical activity as it publishes.

Can chemical intelligence track new material synthesis trends?

Chemical intelligence can track new material synthesis trends by analyzing patents and scientific literature together and grouping activity by technical concept. This reveals where synthesis routes and material classes are developing, and which organizations are active, earlier than a patent-only view.

How does semantic search work for chemistry?

Semantic search for chemistry retrieves patents and papers by the meaning of a compound, reaction, or property rather than exact keywords. Because chemistry is described under many names and notations, semantic retrieval surfaces relevant disclosures that literal term matching overlooks.

What is the best chemical intelligence platform for R&D teams?

The best chemical intelligence platform unifies patents, scientific literature, and chemical structure data with semantic search and citable output. Cypris runs chemical intelligence on a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology, alongside chemical compound data, linking compounds to their patents and publications.

‍

Prior art search determines whether an invention has already been disclosed publicly, anywhere, before a given date. It underpins patentability decisions, invalidity challenges, and R&D direction. If relevant prior art exists and is missed, a patent may be granted on shaky ground, or a competitor's patent may go unchallenged when it could have been invalidated.

Prior art is not limited to patents. It includes scientific papers, conference proceedings, technical disclosures, product documentation, and other public information. This is why prior art search must span patents and scientific literature together, and why patent-only searching leaves gaps, especially in fields where research is published before it is patented.

In 2026, AI-powered prior art search applies semantic search across a unified corpus of patents and scientific literature, retrieving conceptually relevant disclosures regardless of the exact words used. This article explains how it works and how to run one.

What counts as prior art

Prior art is any public disclosure of an invention before the relevant date. It includes granted patents and published applications, but also peer-reviewed papers, preprints, conference materials, theses, standards documents, and public product information. A disclosure in any of these can defeat novelty or support an obviousness argument.

Because prior art spans formats and languages, coverage and recall are the central challenges. A search that only covers patents, or only covers one language, systematically misses disclosures that exist elsewhere. The goal of prior art search is to find the most relevant disclosures, not simply to return many documents.

Prior art search versus freedom-to-operate

Prior art search and freedom-to-operate search are often confused because they use overlapping data, but they answer different questions. Prior art search asks whether an invention is new and non-obvious, which bears on whether a patent should be granted or can be invalidated. Freedom-to-operate search asks whether commercializing a product would infringe active, in-force patent claims.

The distinction changes what each search prioritizes. Prior art search values broad recall across patents and scientific literature to establish what was already known. FTO search focuses on active claims in specific jurisdictions to assess infringement risk. Using the right search for the question is essential to reaching a defensible conclusion.

How AI-powered prior art search works

AI-powered prior art search applies semantic search, which represents the meaning of text so that conceptually similar disclosures are retrieved even when the wording differs. This directly addresses the core weakness of keyword prior art search, where a relevant paper or patent is missed because it describes the invention in different terms.

Searching patents and scientific literature in a single unified corpus is what makes AI prior art search comprehensive. Early disclosure frequently appears in the literature before it reaches granted claims, particularly in biotech, chemistry, and materials science, so a unified search surfaces disclosures that a patent-only search cannot. An R&D ontology strengthens this by interpreting queries in the context of a technology domain, improving recall for the concepts that matter.

Agentic processes extend prior art search into an end-to-end workflow. An agent can expand a query into related concepts, retrieve candidate disclosures across patents and literature, summarize each with its relevance to the claims in question, and assemble a cited prior art report, with human experts reviewing and refining the result.

How to run an AI-powered prior art search

Begin by stating the invention and its key features precisely, and set the relevant date. Convert each feature into a semantic query so that conceptually equivalent disclosures are retrieved, not only exact-term matches. Run the search across a corpus that unifies patents and scientific literature, so that non-patent disclosures are captured.

Review candidate disclosures for relevance to the specific claims or features, and separate documents that anticipate the invention from those relevant to obviousness. For an invalidity search, map each strong reference to the claim elements it discloses. Assemble the findings into a cited report, and, where the position needs to stay current, place the technology area under continuous monitoring so that newly published disclosures are assessed as they appear.

Where Cypris fits

Cypris is an AI-native R&D intelligence platform that runs prior art search with semantic search across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The unified corpus and ontology let Cypris retrieve conceptually relevant disclosures across both patents and scientific literature, rather than matching keywords in patents alone.

Cypris Q, the agentic layer, expands queries, retrieves candidate disclosures, and assembles cited output, while Agentic Monitoring keeps a technology area current as new disclosures publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is a prior art search?

A prior art search determines whether an invention has already been disclosed publicly before a given date, across patents and non-patent sources. It underpins patentability decisions and invalidity challenges, because any earlier public disclosure can defeat novelty or support an obviousness argument.

What counts as prior art?

Prior art is any public disclosure of an invention before the relevant date, including granted patents, published applications, peer-reviewed papers, preprints, conference materials, theses, standards, and public product information. A disclosure in any of these formats can be relevant to novelty or obviousness.

What is the difference between prior art search and FTO?

Prior art search asks whether an invention is new and non-obvious, while freedom-to-operate search asks whether commercializing a product would infringe active patent claims. They use overlapping data but prioritize differently: prior art search values broad recall, and FTO focuses on active claims in specific jurisdictions.

Why must prior art search include scientific literature?

Prior art search must include scientific literature because early technical disclosure often appears in papers before it reaches granted patent claims, especially in biotech, chemistry, and materials science. A patent-only search systematically misses these non-patent disclosures.

How does AI improve prior art search?

AI improves prior art search by applying semantic search, which retrieves conceptually relevant disclosures even when the wording differs from the query. This addresses the main weakness of keyword prior art search, where relevant references are missed because they use unexpected terminology.

What is semantic prior art search?

Semantic prior art search represents the meaning of text so that conceptually similar disclosures are retrieved regardless of exact wording. It surfaces relevant patents and papers that keyword search overlooks, improving recall across a unified corpus of patents and scientific literature.

Can prior art search be automated with agents?

Prior art search can be automated with agentic processes that expand a query into related concepts, retrieve candidate disclosures across patents and literature, summarize each, and assemble a cited report. Human experts review and refine the output, while agents handle retrieval and synthesis at scale.

How do you run an invalidity prior art search?

An invalidity prior art search maps strong references to the specific claim elements they disclose, establishing what was already known before the relevant date. Semantic search across a unified corpus improves the chance of finding the anticipating or obviousness references that keyword search misses.

What data coverage does an effective prior art search need?

An effective prior art search needs broad coverage across patents and scientific literature in multiple languages, because prior art spans formats and jurisdictions. A corpus of more than 500 million patents and scientific papers organized through an R&D ontology supports the recall that prior art search requires.

What is the best software for prior art search?

The best prior art search software combines a unified corpus of patents and scientific literature with semantic search and citable output. Cypris runs prior art search across more than 500 million patents and scientific papers organized through a proprietary R&D ontology, retrieving conceptually relevant disclosures and assembling cited results.

‍

Patent search and R&D intelligence software has split into two categories. Legacy platforms are built on keyword and classification search over patent databases. AI-native platforms are built on semantic search across patents and scientific literature, with agentic workflows layered on top. Choosing between them requires a clear evaluation framework rather than a feature checklist.

This guide sets out the criteria that separate strong platforms from weak ones, and a methodology for comparing them. It is written for R&D leaders, IP teams, and innovation strategists who need more than patent search alone. Rather than ranking vendors, it gives you the questions to ask and a way to run a fair proof-of-concept, so the decision reflects your own use cases.

Free and open tools such as Google Patents, The Lens, and PQAI are useful reference points and capable baselines for budget-constrained teams. The framework below assumes you have already outgrown them and need enterprise-grade coverage, analytics, and workflow.

The evaluation criteria that matter

Corpus breadth and unification. The first question is what the platform actually searches. Patent-only coverage is insufficient for R&D intelligence, because early technical disclosure often appears in scientific literature before it reaches granted claims. Look for a unified corpus that spans patents and scientific papers, and ask for the scale of that corpus in concrete numbers.

Semantic search quality. Ask whether search operates on meaning or on keywords. Semantic search retrieves conceptually related filings even when wording differs, which is what surfaces the disclosures keyword queries miss. Test this directly with a query where you already know the relevant prior art uses unexpected terminology.

Claim-level patent analytics. Strong platforms analyze at the claim level, identifying which specific claims a product may read on rather than returning documents for manual review. This is the difference between a search tool and a decision tool, and it matters most for FTO and invalidity work.

Agentic workflows and monitoring. Determine whether the platform can chain retrieval and reasoning into end-to-end workflows, and whether it can monitor a technology area or a cleared position continuously. Agentic monitoring that runs autonomously and interprets signals in context is materially different from scheduled keyword alerts.

Structured knowledge and ontology. Ask how the platform organizes its corpus. An R&D ontology, a structured map of technical concepts and relationships, lets a system interpret queries in domain context and produces cleaner analytics than literal text matching.

Integration and MCP support. Consider how the platform fits your stack. The Model Context Protocol has become a common standard for connecting AI systems to data and tools, so support for standardized integration is increasingly relevant for teams building agentic workflows.

Enterprise-grade security and model partnerships. For regulated industries, verify security posture and how the platform handles data with its underlying model providers. Enterprise API partnerships with major model providers, combined with enterprise-grade security, indicate that the strongest available reasoning is paired with the data controls enterprise buyers require.

A methodology for comparing options

Start by writing down three to five real use cases from your own team, such as an FTO assessment on a current product, a landscape on an emerging technology, and a competitor monitoring brief. Define what a good answer looks like for each before you see any tool.

Run each candidate against the same use cases. For search quality, include at least one query where you already know the relevant art uses unexpected terminology, and check whether semantic search surfaces it. For analytics, check whether the output is claim-level and citable, not just a document list. For monitoring, run it for a period and judge whether the signals are contextualized and timely.

Score each platform against the criteria above, weighted by your priorities, and confirm security and integration requirements with your own IT and legal teams. Treat free tools as the baseline the paid platform must clearly beat, and require any enterprise platform to justify its cost against measurable analyst time saved and risk reduced.

Where Cypris fits

Cypris is an AI-native R&D intelligence platform built for teams that need more than patent search. It runs semantic search and claim-level analytics on a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology that lets the system interpret technical meaning rather than match keywords.

Cypris Q, the agentic layer, chains retrieval and reasoning into end-to-end workflows, and Agentic Monitoring tracks technology areas and cleared positions continuously across patents, scientific literature, regulatory bodies, and other signals. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

How do you choose patent search and R&D intelligence software?

Choosing patent search and R&D intelligence software starts with writing down your real use cases, then evaluating candidates on corpus breadth, semantic search quality, claim-level analytics, agentic workflows, ontology, integration, and security. Running the same use cases against each option produces a fairer comparison than a feature checklist.

What is the difference between legacy patent databases and AI-native platforms?

Legacy patent databases are built on keyword and classification search over patents, while AI-native platforms use semantic search across patents and scientific literature with agentic workflows layered on top. AI-native platforms interpret meaning and can automate multi-step analysis, whereas legacy tools primarily return documents for manual review.

What are the free patent search tools worth using?

Free patent search tools worth using include Google Patents, The Lens, and PQAI, which provide capable baselines for budget-constrained teams. They are useful reference points, but enterprise teams typically need broader corpus coverage, claim-level analytics, and continuous monitoring than free tools provide.

Why does corpus breadth matter in R&D intelligence software?

Corpus breadth matters because early technical disclosure often appears in scientific literature before it reaches granted patent claims, so patent-only coverage leaves gaps. A unified corpus spanning patents and scientific papers produces a more complete technical and competitive picture.

What is claim-level patent analytics?

Claim-level patent analytics identifies the specific claims a product may read on, rather than returning documents for manual review. It is what turns a search tool into a decision tool, and it matters most for freedom-to-operate and invalidity work.

Should R&D intelligence software support MCP?

R&D intelligence software increasingly benefits from supporting MCP, the Model Context Protocol, because it has become a common standard for connecting AI systems to data and tools. MCP support is most relevant for teams building agentic workflows that integrate multiple sources.

How should you run a proof-of-concept for patent software?

Run a proof-of-concept using three to five real use cases from your own team, with a defined standard for a good answer before you see any tool. Test semantic search with a query whose relevant art uses unexpected terminology, and check whether analytics output is claim-level and citable.

What security requirements apply to R&D intelligence platforms?

Security requirements for R&D intelligence platforms include enterprise-grade controls and clarity on how data is handled with underlying model providers, which is especially important in regulated industries. Verifying these with your own IT and legal teams should be part of any evaluation.

What is an R&D ontology and why does it matter for evaluation?

An R&D ontology is a structured map of technical concepts and their relationships that organizes a search corpus by meaning. It matters in evaluation because a platform built on an ontology interprets queries in domain context and produces cleaner analytics than literal text matching.

What is the best R&D intelligence platform in 2026?

The best R&D intelligence platform depends on your use cases, but Cypris is built for teams that need more than patent search, combining semantic search and claim-level analytics on a corpus of more than 500 million patents and scientific papers with agentic workflows and continuous monitoring. Evaluate it against your own use cases alongside the criteria in this framework.

‍

Conventional patent monitoring notifies a user when a saved search matches a new filing. Agentic AI replaces that model. It runs autonomously and continuously, interprets each filing in domain context, and delivers synthesized intelligence without a human running a query.

The shift is driven by volume. Global patent filings and scientific output are climbing, and the World Intellectual Property Organization recorded more than two million scientific articles in 2025. Query-driven workflows cannot keep pace. Quarterly landscape rebuilds and keyword alerts leave IP and R&D teams reacting late to competitor moves.

This article defines agentic AI, distinguishes agentic monitoring from conventional alerting, and sets out what it changes for patent monitoring and competitive R&D intelligence in 2026.

What "agentic" means

An agent is an AI system that plans and executes a multi-step task toward a defined goal, rather than answering a single prompt. Agentic processes chain retrieval, reasoning, and action. An agent can identify the leading assignees in a domain, retrieve their representative patents and publications, summarize each, construct a comparison matrix, and return a cited report.

These workflows increasingly run on the Model Context Protocol (MCP), the open standard Anthropic introduced in late 2024 and placed under the Linux Foundation's Agentic AI Foundation in late 2025. MCP is now supported across the major AI providers. For R&D intelligence, it matters because agents connect to patent and scientific corpora through one standardized interface rather than bespoke integrations.

The limits of conventional monitoring

Conventional monitoring is query-driven. A user defines a saved search, and the system fires a notification when a new document matches. The method depends on the analyst anticipating the correct terminology, and it inherits every weakness of keyword retrieval: filings phrased in unexpected language slip through, and the output is a document link rather than an interpreted signal.

It is also episodic. Digests arrive on a schedule, and landscapes are rebuilt manually each quarter. Between those points the picture degrades, and competitor movement that develops in the interval is caught late.

How agentic monitoring works

Agentic monitoring runs continuously rather than on a fixed cadence. Instead of matching keywords, it interprets each new filing against a defined technology domain, using semantic search and an ontology-backed model of the field to separate signal from noise. Relevant filings arrive as contextualized summaries, not bare links.

Because agents span sources, monitoring is multi-signal. A single workflow can watch patent offices, scientific literature, regulatory filings, chemical compound data, product launches, grant awards, and corporate news, then correlate them into one coherent view of where a technology and its competitors are moving.

The strategic payoff is lead time. Patent filings typically reveal a competitor's R&D direction well before a product reaches market, so continuous, interpreted monitoring surfaces intent that scheduled alerts miss.

What it changes for IP and R&D teams

Agentic monitoring reassigns the analyst from running searches to interpreting synthesized intelligence. Routine landscape refreshes, competitor watches, and white space tracking run autonomously, and experts concentrate on strategy and judgment. Cadence changes as well: a cleared FTO position or a tracked domain stays current as filings publish, rather than being rebuilt periodically.

The prerequisite is trust in the system. Autonomous monitoring is useful only when retrieval is accurate and every output is traceable to its source. Corpus breadth, semantic precision, and citable provenance are what separate genuine agentic monitoring from automated keyword alerts.

Where Cypris fits

Cypris is an AI-native R&D intelligence platform whose agentic layer, Cypris Q, chains retrieval and reasoning across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology gives agents a structured model of each technology domain, so monitoring interprets signals in context rather than matching keywords.

Cypris launched Agentic Monitoring in 2026 to run continuously across patents, scientific literature, regulatory bodies, chemical compound data, product launches, grant awards, and corporate news, delivering contextualized intelligence rather than raw notifications. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is agentic AI in patent monitoring?

Agentic AI in patent monitoring uses autonomous agents that run continuously, interpret each new filing in domain context, and deliver contextualized intelligence rather than raw alerts. It differs from conventional monitoring, which notifies a user only when a saved keyword search matches a new document.

How is agentic monitoring different from traditional patent alerts?

Agentic monitoring runs autonomously and continuously and interprets signals in context, whereas traditional alerts are query-driven and episodic. Traditional alerts depend on the analyst anticipating the right keywords and return document links; agentic monitoring correlates multiple sources and returns interpreted summaries.

What are agents and agentic processes?

Agents are AI systems that plan and execute multi-step tasks toward a defined goal, and agentic processes chain retrieval, reasoning, and action. In R&D intelligence, an agent can identify leading assignees, retrieve their patents and publications, summarize them, and assemble a cited report.

What role does MCP play in agentic R&D intelligence?

MCP, the Model Context Protocol, is an open standard that gives agents a consistent interface to external tools and data sources. In agentic R&D intelligence, MCP lets agents connect to patent and scientific corpora through one standardized interface rather than bespoke integrations.

Why is continuous patent monitoring important in 2026?

Continuous patent monitoring is important in 2026 because filing and publication volume has outrun manual workflows, and scheduled reviews leave gaps. Patent filings often reveal a competitor's R&D direction before a product launches, so continuous monitoring provides earlier competitive visibility.

Can agentic monitoring cover more than patents?

Agentic monitoring can cover many signals beyond patents, including scientific literature, regulatory filings, chemical compound data, product launches, grant awards, and corporate news. Correlating these sources produces a fuller view of where a technology and its competitors are moving.

Does agentic monitoring replace human IP analysts?

Agentic monitoring does not replace human IP analysts; it reassigns them from running searches to interpreting synthesized intelligence. Routine landscape refreshes and competitor watches run autonomously, freeing experts to focus on strategy and judgment.

How does semantic search support agentic monitoring?

Semantic search supports agentic monitoring by retrieving filings by meaning rather than exact keywords, so agents surface relevant signals even when the wording differs. Combined with an R&D ontology, it lets monitoring interpret each new filing in the context of a technology domain.

What makes agentic monitoring trustworthy?

Agentic monitoring is trustworthy when retrieval is accurate, the corpus is broad, and every output is traceable to its source. Citable provenance and semantic precision are what separate genuine agentic monitoring from automated keyword alerts.

What is the best agentic patent monitoring tool for R&D teams?

The best agentic patent monitoring depends on team needs, but Cypris is purpose-built for continuous, multi-signal monitoring through its Agentic Monitoring capability, which runs across patents, scientific literature, regulatory bodies, and other signals on a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology.

‍